ImmuCell Co. (NASDAQ:ICCC) Sees Large Growth in Short Interest

ImmuCell Co. (NASDAQ:ICCC - Get Free Report) was the target of a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 11,700 shares, an increase of 82.8% from the April 30th total of 6,400 shares. Based on an average trading volume of 23,800 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.2% of the company's stock are sold short.

Institutional Trading of ImmuCell

Institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in shares of ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock valued at $332,000 after buying an additional 7,878 shares during the period. Mesirow Financial Investment Management Inc. lifted its holdings in ImmuCell by 100.0% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company's stock worth $125,000 after acquiring an additional 12,178 shares during the last quarter. Northern Trust Corp boosted its stake in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock valued at $229,000 after acquiring an additional 14,982 shares during the period. Citadel Advisors LLC bought a new position in ImmuCell during the 4th quarter worth $149,000. Finally, Dauntless Investment Group LLC bought a new position in shares of ImmuCell during the fourth quarter worth about $676,000. Institutional investors own 13.47% of the company's stock.

ImmuCell Stock Up 7.5%

ICCC traded up $0.48 on Monday, reaching $6.88. The company's stock had a trading volume of 43,561 shares, compared to its average volume of 22,179. The business's 50 day moving average is $5.41 and its 200 day moving average is $5.06. ImmuCell has a 1 year low of $3.34 and a 1 year high of $6.95. The stock has a market cap of $62.17 million, a price-to-earnings ratio of -13.76 and a beta of 0.23. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.11 and a quick ratio of 1.44.

ImmuCell (NASDAQ:ICCC - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter. The firm had revenue of $8.07 million for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.